Nimbus Therapeutics

📍 Boston, United States🗓 Founded 2009👥 104 employees💰 Last funded Jun 2022
Biotechnology Research🌐 nimbustx.com
Website LinkedIn
Nimbus Therapeutics is a clinical-stage, structure-based drug discovery company developing novel small molecule medicines designed to act against well-validated but difficult-to-drug targets implicated in multiple human diseases. The company advances promising research based on a unique strategy that combines leading-edge computational technologies with a tailored array of machine learning-based predictive modeling approaches. Nimbus pipeline includes a clinical-stage HPK1 inhibitor for the treatment of cancer (NCT05128487), as well as a diverse portfolio of preclinical programs focused on cancer, including a WRN program for MSI-H cancers, autoimmune conditions, and metabolic diseases.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
2009
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
United Kingdom
1
Investor activity2018–2022 · investors recorded per year
201812019120221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Nimbus Therapeutics?
Nimbus Therapeutics has 3 investors on record on gritt.io.
When did Nimbus Therapeutics last raise funding?
The most recent investment in Nimbus Therapeutics recorded on gritt.io was in June 2022.
When was Nimbus Therapeutics founded?
Nimbus Therapeutics was founded in 2009.
What industry is Nimbus Therapeutics in?
Nimbus Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Nimbus Therapeutics based?
Nimbus Therapeutics is headquartered in Boston, United States.